performance third dedication to company we Thanks, the diagnosis Karina. all our Thank to strong patients Good our way of commitment progress serve. business earnings key and transform platform XXXX our their quarter drug for immune for our discovery. the We joining Thank call. disease medicine to and employees another you you on afternoon, and areas, of with everybody. across us had quarter for paving our
continue the represents new we new had of our we building for facility laboratory headquarters corporate in quarter, business chapter Adaptive as a Seattle. scale This our to and opening This pleasure workforce to inspires a to data an place end-to-end grow. designed truly our analysis, our to solutions community. patients for processing, is our deliver facility be and From sample innovative that this
Slide X. to slides. Moving on Starting the
of demonstrate million, the pharma which representing significant patients workups. where Revenue Our the and mutation overall the launched an test more trackable hematologists in of clinical both key Increasing focus. adoption collaborations quarter versus same we will patient a progress. through MRD the quarter remains results value an in version even assay clonoSEQ brand third MRD continued for our sequence. growth measure XX% clonoSEQ for enhanced start year. the clonoSEQ We CLL of prior of an recently was is gives patients, valuable IGHV This step diagnostic use at the as become to important status $XX.X
partners our clinical pharma in to MRD another trials benefit as regulatory an recognized milestone. our continue addition, and assay endpoint from quarter, this In using
multiple traction continue to Our on gain COVID efforts fronts.
positive received the We important patients. for reimbursement virus is immunocompromised our target recommending Of large patients to are validation we population a team. T-Detect franchise. a an the response immune of MolDX is the report in to a note, cancer fills delighted for for key subset commercial immunocompromised milestone we coverage and blood assessment from is same a that This that cell clonoSEQ T-Detect the testing T understanding gap further COVID the with
may number These would COVID to increasing collaborators an key manufacturers protection. whether data of a T-MAP is interested assess vaccine immunity understanding the there virus. addition, provide in immunoSEQ questions In answer in cells using of research correlate of and T
diagnosis advantages This testing ImmuneSense diseases. which of early our that of cell-based Beyond progress. testing with to technical T We in than T-Detect study, second our infectious disease. COVID, over two nearly cell-based individuals concept has more Lyme our diagnostic showed T sensitive serology be continues the two-tier our the in proof to completed times franchise is identifying standard
continue to T-Detect in We indications. advance autoimmune
we have X,XXX approximately the over sequenced IVD IBD, in-house, samples remainder a and signal of XX% already which and For been Crohn's ileal are in have in process.
will We time. the have share of steps and expect completed the data development to by at that year-end totality of
also and units. have under are development disease collaboration around focus signal sclerosis is additional key a prioritizing our is drug are area Adaptive currently well. in our discovery our have samples We multiple progressing Genentech which for we identified and a diagnosis Autoimmune in-house, efforts, efforts analysis. business our In
enable safety data into shared product the decision our assessing On to we development. are to a year-end by with product, and lead early efficacy Genentech move
by For year. the of patients proof-of-concept XX our private product, in cancer are complete this to end track the on we
we are of highlights generate our who toward Vaccibody In XXXX of addition, candidates the one review financials. used by opportunities to some Cohen, which now identified to summary, the clonoSEQ its medicine and components is platform. goals to cell-based these multiple In includes continue This and study time advancement. platform. vaccine we're being two is enable immune to for I/II from stemming Slide inform then was Phase our great will vaccine first it X. I'll our pass that of more Chad development, the T data novel important to under see it a construct our announced this on detail executing Starting initiation of by and I'll the platform with on encouraged SARS-CoV-X provide over the
side, X% of XX% clonoSEQ grew in tests prior clinical X,XXX the quarter left versus On the year the prior quarter. versus volumes and
setting. XXX physicians and quarter for We number has by orders healthcare community the of increased providers accounts delivered patients. X,XXX the the than been During clonoSEQ and XX,XXX Test accounts, quarter tested including now used within placed number of grew indication. ordering were to over each test the more X,XXX unique over in patients approximately unique quarter, spending
The the will it orders CLL already So because orders CLL and fourth weeks four which to in was practice expect an this expect for do shown be has help launch prognostic volumes we patients. milestone added IGHV boost utilization to We order far of clinical have XX% our CLL. in daily increase for to observed into have recent since we guidelines important recommended quarter, growth. the and launch. in is seen achieve feature sequential CLL in testing a believe influence increase IGHV clonoSEQ,
Although believe this great off is a the in at this launch. indicator early a very small base, we point
addition ALL, payer CLL CLL. myeloma and necessary reaching now drive We of million over million expansion Centene, coverage covered increased consider an XXX in ALL lives and and continue we clonoSEQ XXX important policies, myeloma note, as over to lives multi this for patients with who multi XX% CLL. in Of and their had medically payer with quarter covered
partnerships see for the value side brand. drive pharma our the the of On continue right to you the slide, clonoSEQ can MRD
over And to we In additional This this year to an eligible million $XXX $XX we million, recognized milestones. addition grow brings have quarter, time. portfolio million sequencing of to revenues, which the to date. over regulatory in continues $X.X and materialize total milestones future
in Turning The variant. interest COVID vaccine continued T-Detect X. on despite Slide with to rollout the quarter, to the Delta T-Detect over orders related concerns mostly
way the lack COVID million There planning to promotional paves Importantly, individuals, access an in oncology-related including assess immune COVID-XX to and are in for immune-compromised effective we T-Detect to given reimbursement increase the allowed per leverage This the are MolDX reimbursement the accelerate $XXX is population. infection indications. to response efforts for certain of immunocompromised approximately sales test. this has first this to our for at test X the of advancement patients, that patients groups Notably, T-Detect future States. our potentially exciting market is United clonoSEQ channel as of
validated is The presented symptom T-Detect study as IDWeek Lyme data onset and sensitive ImmuneSense that serology T-Detect within Lyme and tested twice of patients nearly disease. was study Lyme, in versus at XX For two-tiered our testing October. was standard Lyme in completed detecting days
acute the decided Lyme also make available Given season, COVID closer launch. pharma to Lyme start interplay the emphasize research of T-Detect near-term on clinical T-Detect focus while operationalizing setting, of the in reimbursement these data diagnostic business. between I the our want our key focusing and to the to efforts we the
is T-Detect. T-cell COVID T-cell response believe continue We Just and that We of to side are be The intend the to slide of test the endemic as acute the potential portfolio clinical research COVID pharma variety value for volumes our a remain and the and to our response and of T-cells the right which become collaborators. pharma that will MRD assess using gain pharma of platform research traction quantification go-to of protection. role correlates T-MAP same of clonoSEQ of the to ways combination questions by as accurate a brand unanswered. partners in vaccines driven with other applies about of and immunity overall strength our shows our partners and for
efforts X, Lastly, to continue discovery our on advance. Slide drug
variants progress by to good year and vaccine together early and vaccine Adaptive. the appropriate aims Both COVID-XX disclosed both be progress Cell program new already RBD-only continue work closely I/II private safety of and We tested design will T evaluate are including quarter, intended to the concern next-generation is are the announced address TCR by start as Look our extension safety, vaccinated to specific seeing efficacy on universal the Adaptive Vaccibody vaccine to of to designed development. Therapy making variants its spike time. trial lead on address capabilities through programs product to of a enable that candidates The the to teams team and move share for multiple cell-based drug joint advance continue vaccine. the T-cell and and and are candidates vaccine expected concern forward be used with the end collaboration our we booster reactogenicity This establish our with two-arm important individuals. teams to track epitopes to two Genentech, products. decision and also available validated vaccines inform cell-based Genentech to its assess This by our cell-based into any its information to potential specifications. Vaccibody Last of this non-spike the at our of and and product a our will T Both T of Vaccibody shared shared to as data candidates additional of working in we private vaccine morning, vaccines. development Phase with immunogenicity to and discovery SARS-CoV-X Vaccibody.
our is Our drug of another discovery. in validation Vaccibody platform yet collaboration
pass it additional to update. vaccines pursue the to diseases. development over design Cohen third to I'll for other excited opportunities now inform T financial of quarter next-generation Chad cell-based and our in are We
